NCT06280703View on ClinicalTrials.gov

A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
HealthyType 1 Diabetes Mellitus
Interventions
DRUG

LY3938577

Administered Intravenously (IV)

DRUG

Placebo

Administered Intravenously (IV)

DRUG

Insulin Degludec

Administered Intravenously (IV)

DRUG

Insulin Lispro

Administered Intravenously (IV)

DRUG

LY3938577

Administered subcutaneously (SC)

DRUG

Placebo

Administered subcutaneously (SC)

DRUG

insulin degludec

Administered SC

Trial Locations (1)

41460

RECRUITING

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY